Mirum Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.3M
Doctors Paid
1,634
Transactions
5,705
2024 Total
$2.9M
Payment Breakdown by Category
Research$4.1M (65.4%)
Consulting$1.6M (25.0%)
Travel$323,189 (5.2%)
Food & Beverage$182,336 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.1M | 798 | 65.4% |
| Consulting Fee | $1.6M | 581 | 25.0% |
| Travel and Lodging | $323,189 | 710 | 5.2% |
| Food and Beverage | $182,336 | 3,558 | 2.9% |
| Grant | $50,000 | 1 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,266 | 10 | 0.7% |
| Education | $736.26 | 42 | 0.0% |
| Entertainment | $373.86 | 4 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $350.00 | 1 | 0.0% |
Payments by Type
Research
$4.1M
798 transactions
General
$2.2M
4,907 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK) | $781,399 | 0 | 142 |
| An Extension Study of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (MARCH-ON) | $672,154 | 0 | 194 |
| A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS) (RISE) | $585,733 | 0 | 74 |
| A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS (RESTORE) | $568,994 | 0 | 26 |
| A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects who Previously Participated in a Maralixibat Study (MERGE) | $438,692 | 0 | 83 |
| A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects with Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) | $332,765 | 0 | 73 |
| A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry to Collect Data on Routine Clinical Care in Patients Treated With Cholbam (Cholic Acid) (REPLACE) | $256,890 | 1 | 132 |
| An Open-Label Study to Evaluate the Safety and Tolerability of Volixibat in Patients with Primary Biliary Cholangitis Currently Being Treated with Obeticholic Acid | $193,680 | 0 | 44 |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients with Alagille Syndrome (LEAP) | $172,406 | 0 | 26 |
| A Maralixibat Expanded Access Program for Patients with Cholestatic Pruritus Associated with Alagille Syndrome (ALGS EAP) | $61,300 | 0 | 3 |
| Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND) | $31,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Tamir Diamond, M.d, M.D | Student in an Organized Health Care Education/Training Program | Philadelphia, PA | $6,106 | $0 |
| Dr. Christopher Chu, Md, MD | Pediatrics | San Diego, CA | $5,939 | $0 |
| Dr. John Bernat, Md,Phd, MD,PHD | Clinical Genetics (M.D.) | Iowa City, IA | $5,918 | $0 |
| Dr. Nisreen Soufi, M.d, M.D | Pediatrics | Duarte, CA | $5,900 | $0 |
| Mohammed Saeed, M.d, M.D | Internal Medicine | Paramus, NJ | $5,884 | $0 |
| Dr. Philip Rosenthal, M.d, M.D | Neurological Surgery | Bakersfield, CA | $5,782 | $0 |
| Dr. Dellys Soler, M.d, M.D | Pediatric Gastroenterology | Orlando, FL | $5,761 | $0 |
| Dr. Brett Hoskins, Do, DO | Pediatric Gastroenterology | Indianapolis, IN | $5,614 | $0 |
| Amrita Narang, Md, MD | Pediatrics | Palo Alto, CA | $5,517 | $0 |
| Dr. Anupama Chawla, M.d, M.D | Pediatric Gastroenterology | Stony Brook, NY | $5,448 | $0 |
| Zineb Ammous, M.d, M.D | Clinical Genetics (M.D.) | Topeka, IN | $5,448 | $0 |
| Dr. Silvia Teixeira Vilarinho, M.d., Ph.d, M.D., PH.D | Gastroenterology | New Haven, CT | $5,022 | $0 |
| Dr. Nadia Ovchinsky | Pediatric Gastroenterology | New York, NY | $5,013 | $0 |
| Dr. Janis Stoll, Md, MD | Pediatrics | Saint Louis, MO | $5,011 | $0 |
| Dr. Scott Brun, Md, MD | Ophthalmology | North Chicago, IL | $4,500 | $0 |
| Jiten Kothadia, M.d, M.D | Internal Medicine | Memphis, TN | $4,424 | $0 |
| Dr. Wikrom Karnsakul, M.d, M.D | Pediatric Gastroenterology | Baltimore, MD | $4,357 | $0 |
| John Lieske, M.d, M.D | Nephrology | Rochester, MN | $3,900 | $0 |
| Kathleen Schwarz, M.d, M.D | Pediatrics | San Diego, CA | $3,712 | $0 |
| Aalam Sohal | Hepatology | Seattle, WA | $3,533 | $0 |
| Dr. Voytek Slowik, M.d, M.D | Pediatrics | Kansas City, MO | $3,458 | $0 |
| Dr. Olumuyiwa Awoniyi, Md/Ph.d, MD/PH.D | Transplant Hepatology | Cleveland, OH | $3,202 | $0 |
| Sunil Mehta, Md, MD | Child & Adolescent Psychiatry | Los Angeles, CA | $3,200 | $0 |
| Bernadette Vitola, Md, MD | Pediatric Transplant Hepatology | Milwaukee, WI | $3,080 | $0 |
| Dr. Emily Perito, M.d, M.D | Pediatrics | San Francisco, CA | $2,951 | $0 |
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. has made $6.3M in payments to 1,634 healthcare providers, recorded across 5,705 transactions in the CMS Open Payments database. In 2024, the company paid $2.9M. The top product by payment volume is Livmarli ($4.1M).
Payments were distributed across 94 medical specialties. The top specialty by payment amount is Pediatric Gastroenterology ($779,526 to 343 doctors).
Payment categories include: Food & Beverage ($182,336), Consulting ($1.6M), Research ($4.1M), Travel & Lodging ($323,189).
Mirum Pharmaceuticals, Inc. is associated with 1 products in the CMS Open Payments database.